We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Microparticles Coated with Apoptotic Antigens Blunt Autoimmune Attack

By LabMedica International staff writers
Posted on 29 Nov 2012
The molecular processes responsible for autoimmune diseases such as multiple sclerosis (MS) can be shut down by exposing cells in the immune system to microparticles coated with antigens from cells that have been reduced to fragments by apoptosis.


Investigators at Northwestern University (Chicago, IL, USA) had previously shown that antigen-bound apoptotic cells could be injected safely into patients with MS. More...
While this treatment induced T cell tolerance that prevented further autoimmune attack and slowed progression of the disease, it was not practical for routine clinical use. Senior author Dr. Stephen Miller, professor of immunology at Northwestern University, explained, "Cellular therapy is extremely expensive as it needs to be carried out in a large medical center that has the capability to isolate patient's white blood cells under sterile conditions and to re-infuse those antigen-coupled cells back into the patients. It is a costly, difficult, and time-consuming procedure."

A search for alternative methods to replace living cells as transporters of apoptotic antigens led to the development of suitable synthetic microparticles. In a paper published in the November 18, 2012, online edition of the journal Nature Biotechnology the investigators described the preparation of polystyrene or biodegradable poly(lactide-co-glycolide) microparticles coated with antigens relevant to a mouse model of MS (relapsing experimental autoimmune encephalomyelitis).

Mice with relapsing experimental autoimmune encephalomyelitis were treated by intravenous infusion of the microparticles. Results showed that treatment with the microparticles prevented the onset and modified the course of the disease. These beneficial effects required microparticle uptake by marginal zone macrophages expressing the scavenger receptor MARCO and were mediated in part by the activity of regulatory T cells, abortive T-cell activation, and T-cell anergy.

The biodegradable poly(lactide-co-glycolide) used to formulate the microparticles has already been approved by the [US] Food and Drug Administration and is currently used in sutures as well as in clinical trials to deliver anticancer agents. Dr. Miller said, "I think we have come up with a very potent way to induce tolerance that can be easily translated into clinical practice. We are doing everything we can now to take this forward."

Related Links:

Northwestern University




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.